About 100 reports

  • HEART TRANSPLANT REJECTION - PIPELINE BY HEAT BIOLOGICS INC, H1 2018
  • HEART TRANSPLANT REJECTION - PIPELINE BY NOXXON PHARMA AG, H1 2018

Heart transplant replaces an injured or diseased heart with a healthy one.

  • Heart Transplant
  • Medical Biotechnology
  • Targeted Therapy
  • World
  • Product Initiative
  • Target
  • Target

HEART TRANSPLANT REJECTION THERAPEUTICS CLINICAL TRIALS, GLOBAL, BY END POINT STATUS, 2017* CLINICAL TRIALS BY END POINT STATUS HEART TRANSPLANT REJECTION THERAPEUTICS CLINICAL TRIALS, GLOBAL, BY END POINT STATUS, 2017* HEART TRANSPLANT REJECTION

  • Clinical Trial
  • Heart Transplant
  • Pharmaceutical
  • Targeted Therapy
  • Novartis AG

Liver transplant replaces an injured or diseased liver with a healthy one.

  • General Medicine And Specialty Medicine
  • Targeted Therapy
  • United States
  • World
  • Product Initiative

The prominent features of this report are - ##.

  • Clinical Trial
  • Monoclonal Antibody
  • Pharmaceutical
  • Targeted Therapy
  • World

The prominent features of this report are - ##.

  • Clinical Trial
  • Monoclonal Antibody
  • Pharmaceutical
  • Targeted Therapy
  • World

Significant survival advantages for the abatacept group were demonstrated at one-year post-transplant.

  • Immunotherapy
  • Monoclonal Antibody
  • Targeted Therapy
  • Therapy
  • Bristol-Myers Squibb Company
  • DORMANT PRODUCTS, H2 2018 (CONTD..1), H2 2018

## ## ## Universities/ Institutes ## ## ## ## ## ## PRODUCTS UNDER DEVELOPMENT BY INDICATION NUMBER OF PRODUCTS UNDER DEVELOPMENT BY TOP ## INDICATIONS, H## 2018 NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H## 2018 Indication Source: Global Markets Dire

  • Immunotherapy
  • Monoclonal Antibody
  • Oncology
  • Targeted Therapy
  • Apexigen, Inc.
  • 5. All the trials included are unique trials.

P. A. ", Italy) GDCT## GDC##, MFM## Immunology Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Lung Transplant Rejection, Lupus Nephritis, Transplant Rejection Completed Phase I Interventional

  • Clinical Trial
  • Hospital
  • Targeted Therapy
  • World
  • Product Initiative

Patients will be randomized in a ##:##:## fashion to placebo or one of two different doses of AG## on a background of stable heart failure therapy.

  • Endocrine Disease
  • Targeted Therapy
  • United States
  • Product Initiative
  • Alnylam Pharmaceuticals, Inc.

The prominent features of this report are - ##.

  • Clinical Trial
  • Targeted Therapy
  • World
  • Product Initiative
  • Conatus Pharmaceuticals Inc.
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Blood Disease
  • Clinical Trial
  • Leukemia
  • Targeted Therapy
  • Novartis AG

CLINICAL TRIALS BY PHASE IN G## COUNTRIES LUNG TRANSPLANT REJECTION THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY PHASE, 2017* LUNG TRANSPLANT REJECTION THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY PHASE, 2017* LUNG TRANSPLANT REJECTION THERAPEUTICS, G## COUNTRIES, CLINIC

  • Clinical Trial
  • Lung Transplant
  • Monoclonal Antibody
  • Targeted Therapy
  • Novartis AG
  • DORMANT PRODUCTS, H2 2019 (CONTD..1), H2 2019

## Total ## Products in Phase II/ III and I/ II are reflected under Phase III and Phase II, respectively Source: Global Markets Direct NUMBER OF PRODUCTS UNDER DEVELOPMENT BY STAGE OF DEVELOPMENT, H## 2019 Stage of Development Number of Products Under Development PRODUCTS UNDER DEVELO

  • Immunotherapy
  • Monoclonal Antibody
  • Oncology
  • Targeted Therapy
  • Apexigen, Inc.
  • CLINICAL TRIAL PROFILE SNAPSHOTS

The prominent features of this report are - ##.

  • Medical Biotechnology
  • Neurological Disorder
  • Targeted Therapy
  • World
  • Product Initiative
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2019 (CONTD..4), H1 2019
  • DORMANT PRODUCTS, H1 2019 (CONTD..1), H1 2019

MP## is currently in phase ##.

  • Immunotherapy
  • Targeted Therapy
  • World
  • Product Initiative
  • Apexigen, Inc.
  • CLINICAL TRIAL PROFILE SNAPSHOTS

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Autoimmune Disease
  • Medical Biotechnology
  • Targeted Therapy
  • World
  • Product Initiative

The prominent features of this report are - ##.

  • Cardiology
  • Cardiovascular Disease
  • Clinical Trial
  • Targeted Therapy
  • World
  • CLINICAL TRIAL PROFILE SNAPSHOTS
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

None of these QT abnormalities resulted in adverse cardiac events.

  • Clinical Trial
  • Drug Development
  • Pharmaceutical
  • Targeted Therapy
  • World
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Clinical Trial
  • Ophthalmology
  • Targeted Therapy
  • World
  • Novartis AG

Reddy' s Under Fasting Conditions GDCT## NCT##, BA## Immunology Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection Completed Phase I Interventional tacrolimus Dr.

  • Clinical Trial
  • Monoclonal Antibody
  • Targeted Therapy
  • Transplantation
  • Novartis AG

GDCT ID is the unique ID of GlobalData' s Pharma Intelligence Center clinical trial database Clinical Trial profile. ## Trial Title Official Title Trial Identifier Secondary ID(s) Therapy Area Indication(s) Biomarker(s) Trial Status Trial Phase Study Type Drug(s)/ Molecule(s) Sponsor

  • Clinical Trial
  • Monoclonal Antibody
  • Pharmaceutical
  • Targeted Therapy
  • World

Significant survival advantages for the abatacept group were demonstrated at one-year post-transplant.

  • Arthritis
  • Immunotherapy
  • Targeted Therapy
  • Therapy
  • Bristol-Myers Squibb Company

Hoffmann-La Roche Ltd ## ## ## ## ## ## Clinical Research and Biosciences India Private Limited (Inactive) ## ## ## ## ## ## ClinAssess GmbH ## ## ## ## ## ## Bavarian Nordic A/ S ## ## ## ## ## ## AstraZeneca Plc ## ## ## ## ## ## APT

  • Medical Biotechnology
  • Pharmaceutical
  • Targeted Therapy
  • World
  • Product Initiative

The prominent features of this report are - ##.

  • Clinical Trial
  • Drug Development
  • Targeted Therapy
  • World
  • Product Initiative

TRANSPLANT REJECTION IS ONE OF THE KEY CHALLENGES OF ORGAN TRANSPLANTATION.

  • Health Services
  • Targeted Therapy
  • Therapy
  • United States
  • Product Initiative
  • CLINICAL TRIAL PROFILE SNAPSHOTS

The prominent features of this report are - ##.

  • Targeted Therapy
  • Therapy
  • World
  • Product Initiative
  • Novartis AG
  • 5. All the trials included are unique trials.
  • Clinical Trial Profile Snapshots

Hoffmann-La Roche Ltd ## ## ## ## ## ## ## ## Sanofi ## ## ## ## ## ## ## ## Johnson & Johnson ## ## ## ## ## ## ## ## Astellas Pharma Inc ## ## ## ## ## ## ## ## Takeda Pharmaceutical Co Ltd ## ## ## ## ## ## ## ## Incyte Corp ## ## ## ## ## ## ## ## Bellicum Pharmaceuticals Inc ## ##

  • Monoclonal Antibody
  • Pharmaceutical
  • Targeted Therapy
  • United States
  • World
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Clinical Trial
  • Drug Development
  • Medical Biotechnology
  • Targeted Therapy
  • World
  • EVEROLIMUS - DRUG PROFILE

Novartis Pharmaceuticals registered a one year, multicenter, open-label, single arm, pilot Phase III study of the renal safety of Everolimus in addition to Cyclosporine microemulsion in cardiac transplant recipients.

  • Cancer
  • Targeted Therapy
  • Therapy
  • United States
  • Product Initiative

Hoffmann-La Roche Ltd ## ## ## ## ## ## ## Alexion Pharmaceuticals Inc ## ## ## ## ## ## ## Astellas Pharma Inc ## ## ## ## ## ## ## Cytokinetics Inc ## ## ## ## ## ## ## Quintiles IMS Holdings Inc ## ## ## ## ## ## ## CuraVac Inc ## ## ## ## ## ## ## CSL Ltd ##

  • Clinical Trial
  • Monoclonal Antibody
  • Targeted Therapy
  • World
  • Product Initiative